Cardiff Oncology Publishes Phase 1b KRAS-mutated mCRC Trial Data in Clinical Cancer Research

Cardiff Oncology, a biotechnology firm at the clinical stage, is making significant strides in the development of innovative cancer treatments through the use of Polo-like kinase 1 (PLK1) inhibition. The company's flagship drug, onvansertib, is a PLK1 inhibitor that is being tested in combination with standard-of-care (SoC) treatments for various cancers, with a focus on those with unmet needs.

Recent research findings from Cardiff's Phase 1b/2 study have been published in the Clinical Cancer Research journal, highlighting the safety and potential efficacy of onvansertib when used in conjunction with SoC chemotherapy and bevacizumab for the second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). The study's results suggest that the combination therapy is well-tolerated and could offer sustained responses for patients with different KRAS mutations.

Onvansertib has demonstrated its potential not only as a single agent but also when combined with various chemotherapy drugs for treating solid tumors. The positive outcomes from the Phase 1b study have prompted further investigation into a first-line trial for RAS-mutated mCRC, known as CRDF-004.

Dr. Fairooz Kabbinavar, the Chief Medical Officer at Cardiff Oncology and a lead author of the study, emphasized the importance of the Phase 1b study for patients with KRAS-mutated mCRC who have limited treatment options. The study showed improved objective response rates and median progression-free survival compared to historical data. Moreover, the combination of FOLFIRI, bevacizumab, and onvansertib proved effective across various KRAS mutations.

Cardiff Oncology's broader strategy involves targeting the vulnerabilities of tumors to overcome resistance to treatment and provide better clinical benefits than SoC treatments alone. Onvansertib is also being evaluated in clinical programs for other cancer types, such as metastatic pancreatic ductal adenocarcinoma, as well as in investigator-initiated trials for small cell lung cancer and triple-negative breast cancer.

The company's commitment to advancing cancer therapies is evident through its ongoing research and development efforts. With the positive results from the Phase 1b study and the initiation of the CRDF-004 trial, Cardiff Oncology is well-positioned to contribute to the field of oncology and potentially improve patient outcomes.